Cargando…
Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices
Atrial fibrillation (AF) is an established risk factor for a first or recurrent stroke. Despite proven efficacy in preventing stroke in patients with AF, warfarin is underused, partly due to safety concerns. Recent randomized trials have shown that non-vitamin K antagonist oral anticoagulants (NOACs...
Autor principal: | Saraiva, José Francisco Kerr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986671/ https://www.ncbi.nlm.nih.gov/pubmed/29488150 http://dx.doi.org/10.1007/s40119-018-0106-1 |
Ejemplares similares
-
Choice of Oral Anticoagulant: Outcomes in Atrial Fibrillation Patients Post-Stroke Despite Direct Oral Anticoagulant Use
por: Duong, Eric, et al.
Publicado: (2023) -
Newer Oral Anticoagulants: Stroke Prevention and Pitfalls
por: Patel, Anand, et al.
Publicado: (2016) -
Adherence to oral anticoagulant therapy in secondary stroke prevention – impact of the novel oral anticoagulants
por: Luger, Sebastian, et al.
Publicado: (2015) -
Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment
por: Wilke, Thomas, et al.
Publicado: (2019) -
Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
por: Turpie, Alexander GG
Publicado: (2014)